Investing.com -- Sartorius AG (ETR: SATG ) posted a jump in first-quarter earnings, driven by growth across both its Bioprocess Solutions and Lab Products divisions.

Underlying net profit soared 21.4% to 85 million euros. Underlying earnings per ordinary share increased to 1.22 euros from 1.01 euros in the prior-year period.

Revenue grew 7.7% to 883 million euros from 819.6 million euros a year earlier. On a constant currency basis, the increase was 6.5%.

Sartorius reported a strong jump in profitability, with underlying EBITDA rising 12.2% to 263 million euros in the first quarter. The EBITDA margin expanded to 29.8%.

Order intake also came in ahead of sales revenue, pushing the book-to-bill ratio above one.

“Sartorius has gotten off to a very good start to the new year, in particular the strong trend in our consumables business continues. By contrast, customers are still cautious about investing in lab instruments and bioprocessing equipment, as expected,” said Sartorius CEO Dr. Joachim Kreuzburg.

“The fundamental growth drivers of our industry are increasingly playing the central role again. Demand for biologics – often the only effective therapies for severe diseases – will continue to rise sustainably, along with the strong need for innovative technologies that make their development and manufacture faster and more efficient."

Looking ahead, the German pharmaceutical and laboratory equipment supplier said it expects group sales to grow around 6% in 2025, with a forecast range of plus or minus two percentage points due to elevated market volatility.

By division, Bioprocess Solutions is projected to expand around 7%, while Lab Products & Services is expected to grow about 1%.

The company also guided for an adjusted EBITDA margin of 29% to 30% at the group level for 2025.